Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy

被引：3
|
作者：
Wu, Jiyong [1 ]
Nie, Jing [1 ]
Luan, Yepeng [2 ]
Ding, Yanjiao [1 ]
机构：
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
来源：
CURRENT MEDICINAL CHEMISTRY | 2023年 / 30卷 / 20期
基金：
美国国家科学基金会;
关键词：
Histone deacetylase; hybrid; multitarget inhibitors; antitumor; cancer therapy; bifunctional agent; SHOCK-PROTEIN; 90; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; HYDROXAMIC ACID-DERIVATIVES; BETA-CARBOLINE ALKALOIDS; NITRIC-OXIDE DONORS; IN-VITRO EVALUATION; DEMETHYLASE; LSD1; PROSTATE-CANCER; HDAC INHIBITORS; ANDROGEN RECEPTOR;
D O I：
10.2174/0929867329666220826163626
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Inhibition of histone deacetylases (HDACs) has proven to be an effective strategy for cancer therapy. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. An agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDACi. Representative classes of reported hybrid HDACis are reviewed here to shed light on the design of novel hybrid HDACis for cancer therapy.
引用
收藏
页码：2267 / 2311
页数：45
相关论文
共 50 条
  • [21] Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment
    Shirbhate, Ekta
    Veerasamy, Ravichandran
    Boddu, Sai H. S.
    Tiwari, Amit K.
    Rajak, Harish
    DRUG DISCOVERY TODAY, 2022, 27 (06) : 1689 - 1697
  • [22] Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance
    Ganai, Shabir Ahmad
    PHARMACEUTICAL BIOLOGY, 2016, 54 (09) : 1926 - 1935
  • [23] Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
    Zhang, Lei
    Han, Yantao
    Jiang, Qixiao
    Wang, Chunbo
    Chen, Xuehong
    Li, Xiaoguang
    Xu, Fuming
    Jiang, Yuqi
    Wang, Qiang
    Xu, Wenfang
    MEDICINAL RESEARCH REVIEWS, 2015, 35 (01) : 63 - 84
  • [24] Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Estrov, Zeev
    Borthakur, Gautam
    Cortes, Jorge
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2012, 36 (09) : 1124 - 1127
  • [25] Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
    Frew, Ailsa J.
    Lindemann, Ralph K.
    Martin, Ben P.
    Clarke, Christopher J. P.
    Sharkey, Janelle
    Anthony, Desiree A.
    Banks, Kellie-Marie
    Haynes, Nicole M.
    Gangatirkar, Pradnya
    Stanley, Kym
    Bolden, Jessica E.
    Takeda, Kazuyoshi
    Yagita, Hideo
    Secrist, J. Paul
    Smyth, Mark J.
    Johnstone, Ricky W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (32) : 11317 - 11322
  • [26] Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
    Grabarska, Aneta
    Luszczki, Jarogniew J.
    Nowosadzka, Ewa
    Gumbarewicz, Ewelina
    Jeleniewicz, Witold
    Dmoszynska-Graniczka, Magdalena
    Kowalczuk, Krystyna
    Kupisz, Krzysztof
    Polberg, Krzysztof
    Stepulak, Andrzej
    JOURNAL OF CANCER, 2017, 8 (01): : 19 - 28
  • [27] Targeting novel nuclear receptors with histone deacetylase inhibitor combination therapy in bladder cancer
    Abedin, SA
    Veerakumarasivam, A
    Kelly, J
    Neal, DE
    Mills, I
    Campbell, M
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 36 - 36
  • [28] Dietary Sulforaphane, a Histone Deacetylase Inhibitor for Cancer Prevention
    Ho, Emily
    Clarke, John D.
    Dashwood, Roderick H.
    JOURNAL OF NUTRITION, 2009, 139 (12): : 2393 - 2396
  • [29] Epigenetic therapy of cancer with histone deacetylase inhibitors
    Lakshmaiah, K. C.
    Jacob, Linu A.
    Aparna, S.
    Lokanatha, D.
    Saldanha, Smitha C.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (03) : 469 - 478
  • [30] Histone Deacetylase Inhibitors: Potential in Cancer Therapy
    Marks, P. A.
    Xu, W. -S.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 107 (04) : 600 - 608
12345